Christoph C. Carter

Infectious Disease
1959 NE Pacific St # 1469
Seattle, WA 98195

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications

HIV acquisitions, safety, and pharmacokinetics of lenacapavir for HIV pre-exposure prophylaxis in pregnant and lactating women (PURPOSE 1): a substudy of a phase 3, randomised controlled trial.

HIV acquisitions, safety, and pharmacokinetics of lenacapavir for HIV pre-exposure prophylaxis in pregnant and lactating women (PURPOSE 1): a substudy of a phase 3, randomised controlled trial.

Journal: The lancet. HIV
Published: April 10, 2026

Resistance Analyses of Lenacapavir, Emtricitabine/Tenofovir Alafenamide and Emtricitabine/Tenofovir Disoproxil Fumarate in the PURPOSE 1 and 2 Studies.

Resistance Analyses of Lenacapavir, Emtricitabine/Tenofovir Alafenamide and Emtricitabine/Tenofovir Disoproxil Fumarate in the PURPOSE 1 and 2 Studies.

Journal: The Journal of infectious diseases
Published: June 21, 2025

Pharmacokinetics and safety of once-yearly lenacapavir: a phase 1, open-label study.

Pharmacokinetics and safety of once-yearly lenacapavir: a phase 1, open-label study.

Journal: Lancet (London, England)
Published: February 10, 2025

Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons.

Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons.

Journal: The New England journal of medicine
Published: November 27, 2024

Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women.

Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women.

Journal: The New England journal of medicine
Published: July 24, 2024

HIV Preexposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate Among Cisgender Women.

HIV Preexposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate Among Cisgender Women.

Journal: JAMA
Published: March 01, 2024

Gender Affirming Hormones Do Not Affect the Exposure and Efficacy of F/TDF or F/TAF for HIV Preexposure Prophylaxis: A Subgroup Analysis from the DISCOVER Trial.

Gender Affirming Hormones Do Not Affect the Exposure and Efficacy of F/TDF or F/TAF for HIV Preexposure Prophylaxis: A Subgroup Analysis from the DISCOVER Trial.

Journal: Transgender health
Published: February 05, 2024

Type 1 Human Immunodeficiency Virus (HIV-1) Incidence, Adherence, and Drug Resistance in Individuals Taking Daily Emtricitabine/Tenofovir Disoproxil Fumarate for HIV-1 Pre-exposure Prophylaxis: Pooled Analysis From 72 Global Studies.

Type 1 Human Immunodeficiency Virus (HIV-1) Incidence, Adherence, and Drug Resistance in Individuals Taking Daily Emtricitabine/Tenofovir Disoproxil Fumarate for HIV-1 Pre-exposure Prophylaxis: Pooled Analysis From 72 Global Studies.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: October 30, 2023

HIV-1 infection kinetics, drug resistance, and long-term safety of pre-exposure prophylaxis with emtricitabine plus tenofovir alafenamide (DISCOVER): week 144 open-label extension of a randomised, controlled, phase 3 trial.

HIV-1 infection kinetics, drug resistance, and long-term safety of pre-exposure prophylaxis with emtricitabine plus tenofovir alafenamide (DISCOVER): week 144 open-label extension of a randomised, controlled, phase 3 trial.

Journal: The lancet. HIV
Published: August 23, 2023

Dengue activates mTORC2 signaling to counteract apoptosis and maximize viral replication.

Dengue activates mTORC2 signaling to counteract apoptosis and maximize viral replication.

Journal: Frontiers in cellular and infection microbiology
Published: June 28, 2022

Proactive strategies to optimize engagement of Black, Hispanic/Latinx, transgender, and nonbinary individuals in a trial of a novel agent for HIV pre-exposure prophylaxis (PrEP).

Proactive strategies to optimize engagement of Black, Hispanic/Latinx, transgender, and nonbinary individuals in a trial of a novel agent for HIV pre-exposure prophylaxis (PrEP).

Journal: PloS one
Published: January 28, 2022

Weight Change Following Antiretroviral Therapy Switch in People With Viral Suppression: Pooled Data from Randomized Clinical Trials.

Weight Change Following Antiretroviral Therapy Switch in People With Viral Suppression: Pooled Data from Randomized Clinical Trials.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: February 18, 2021
Showing 1-12 of 23

Last Updated: 09/26/2026